Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.

@article{Kwo2012PhaseIR,
  title={Phase III results in Genotype 1 na{\"i}ve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.},
  author={Paul Y. Kwo},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2012},
  volume={32 Suppl 1},
  pages={39-43}
}
The addition of telaprevir or boceprevir to pegylated interferon (PEG-INF) and ribavirin (RBV) has improved sustained viral response (SVR) rates in genotype-1-infected individuals. The recent publication of Phase III trials has made it possible to examine pretreatment and on-treatment predictors of response in genotype 1 naïve patients. Both telaprevir- and boceprevir-based therapy improve SVR rates in most treatment groups including individuals who are difficult-to-treat such as those with a… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…